Prostate cancer (PCa) is one of the common malignancies in male adults. In the era of precision medicine, many other novel agents targeting advanced prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC), are currently being evaluated. Among all these candidate therapies, poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage response (DDR) pathway has proven improving survival outcomes in clinical trials. In this review, we focus on recent advances in biology and clinical implication of DDR pathway and aim to discuss the latest results in advanced prostate cancer, especially mCRPC.
CITATION STYLE
Xu, C., Mao, S., & Jiang, H. (2020). Recent advances in DNA repair pathway and its application in personalized care of metastatic castration-resistant prostate cancer (mCRPC). In Methods in Molecular Biology (Vol. 2204, pp. 75–89). Humana Press Inc. https://doi.org/10.1007/978-1-0716-0904-0_7
Mendeley helps you to discover research relevant for your work.